Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001601485-26-000035
Filing Date
2026-04-29
Accepted
2026-04-29 16:06:17
Documents
16
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A angn-20251231.htm   iXBRL 10-K/A 533258
2 EX-31.1 elicio-ex311to10xk_aapri.htm EX-31.1 1331
3 EX-31.2 elicio-ex312to10xk_aapri.htm EX-31.2 1376
7 GRAPHIC elicio-ex311to10xk_aapri001.jpg GRAPHIC 63303
8 GRAPHIC elicio-ex312to10xk_aapri001.jpg GRAPHIC 65899
  Complete submission text file 0001601485-26-000035.txt   984305

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT angn-20251231.xsd EX-101.SCH 2396
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT angn-20251231_lab.xml EX-101.LAB 37482
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT angn-20251231_pre.xml EX-101.PRE 21992
20 EXTRACTED XBRL INSTANCE DOCUMENT angn-20251231_htm.xml XML 9393
Mailing Address 451 D STREET, 5TH FLOOR BOSTON MA 02210
Business Address 451 D STREET, 5TH FLOOR BOSTON MA 02210 (857) 209-0050
Elicio Therapeutics, Inc. (Filer) CIK: 0001601485 (see all company filings)

EIN.: 113430072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39990 | Film No.: 26915891
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)